EZH2 and acute myeloid leukemia: To further explore the role of EZH2 mutations in human disease, we extended our analysis into a large cohort of AML patient samples (n = 2,434) from the National Cancer Research Institute (NCRI) AML studies (AML14, AML15, AML16, AML17, and LI1).